Stock Events

Stock Events

Relmada Therapeutics 

$5.24
39
-$0.22-4.03% Friday 20:00
+$0.10+1.91%Friday 23:55After hours

Statistics

Day High
5.27
Day Low
5.21
52W High
8
52W Low
0.55
Volume
251,622
Avg. Volume
-
Mkt Cap
550.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.72
-0.55
-0.37
-0.2
Expected EPS
-0.199533
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-57.39MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLMD. It's not an investment recommendation.
Alphabet
6
GOOGL
Rigetti Computing
6
RGTI
Microsoft
5
MSFT
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap8.66B
Alkermes develops treatments for major depressive disorder and other central nervous system disorders, overlapping with Relmada's focus.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, directly competing with Relmada's offerings.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad range of products for neurological and psychiatric conditions, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries has a focus on CNS and pain, areas that Relmada is also targeting.
Novartis
NVS
Mkt Cap293.94B
Novartis offers medications for a wide range of neurological conditions, competing in the same market as Relmada.
Merck
MRK
Mkt Cap305.12B
Merck & Co. has initiatives in brain health, including treatments for conditions that Relmada targets.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie has a growing portfolio in neuroscience, including treatments for psychiatric disorders.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb has a diverse neuroscience portfolio, making it a competitor in the mental health treatment market.

About

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Show more...
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Employees
17
Country
United States
ISIN
US75955J4022

Listings

STU
DE
4E2.STU
F
DE
4E2.F
MU
DE
4E2.MU
XNAS
US
RLMD

0 Comments

Share your thoughts

FAQ

What is Relmada Therapeutics stock price today?▼
The current price of RLMD is $5.24 USD — it has decreased by -4.03% in the past 24 hours. Watch Relmada Therapeutics stock price performance more closely on the chart.
What is Relmada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Relmada Therapeutics stocks are traded under the ticker RLMD.
Is Relmada Therapeutics stock price growing?▼
RLMD stock has fallen by -18.25% compared to the previous week, the month change is a -22.14% fall, over the last year Relmada Therapeutics has showed a +808.15% increase.
What is Relmada Therapeutics market cap?▼
Today Relmada Therapeutics has the market capitalization of 550.13M
When is the next Relmada Therapeutics earnings date?▼
Relmada Therapeutics is going to release the next earnings report on August 06, 2026.
What were Relmada Therapeutics earnings last quarter?▼
RLMD earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.2 USD resulting in a -9.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Relmada Therapeutics revenue for the last year?▼
Relmada Therapeutics revenue for the last year amounts to 0 USD.
What is Relmada Therapeutics net income for the last year?▼
RLMD net income for the last year is -57.39M USD.
How many employees does Relmada Therapeutics have?▼
As of July 19, 2026, the company has 17 employees.
In which sector is Relmada Therapeutics located?▼
Relmada Therapeutics operates in the Health & Wellness sector.
When did Relmada Therapeutics complete a stock split?▼
The last stock split for Relmada Therapeutics was on September 30, 2019 with a ratio of 1:4.
Where is Relmada Therapeutics headquartered?▼
Relmada Therapeutics is headquartered in Coral Gables, United States.